Kidney outcomes in four major clinical trials evaluating glucagon-like peptide-1 receptor agonist medications in patients with type 2 diabetes.
Pfeffer MA , et al.. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373:2247–2257.
Mann JFE , et al.. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377:839–848.
Marso SP , et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311–322.
Tuttle KR , et al.. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018; 6:605–617.
Marso SP , et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375:1834–1844.
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes–2019. Diabetes Care 2019; 42:S90–S102.
Tuttle KR , et al.. CKD outcomes in type 2 diabetes and moderate-to-severe CKD treated with dulaglutide versus insulin glargine: AWARD-7 [Poster]. JASN Kidney Week Edition Abstract Supplement 2018. 2018; Poster TH-OR033.
Mann JFE , et al.. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation 2018; 138:2908–2918.
Sun F , et al.. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract 2015; 110:26–37.
Potts JE , et al.. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One 2015; 10:e0126769.
Vilsboll T , et al.. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344:d7771.
Dieter BP , Alicic RZ , Tuttle KR . GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. Am J Physiol Renal Physiol 2018; 315:F1519–F1525.
Tanaka T , et al.. The potential for renoprotection with incretin-based drugs. Kidney Int 2014; 86:701–711.